Tricyclic compounds as TXA.sub.2 antagonists
US5302596A · kind A · utility
28Cited by
16References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 23, 1992 |
| Grant date | Apr 12, 1994 |
| Priority date | — |
| Expiry date | Nov 23, 2012 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Novel tricyclic compound represented by formula ##STR1## possess a TXA.sub.2 biosynthesis inhibiting activity and/or a TXA.sub.2 receptor antagonizing activity, and are expected to have preventive and therapeutic effects on ischemic diseases, cerebro-vascular diseases, etc.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.